NGX6 基因对高转移鼻咽癌细胞株 5-8F 细胞的影响

NGX6 是一个新克隆的鼻咽癌候选抑瘤基因 . 为进一步研究其功能,在构建 NGX6 的真核表达载体 NGX6/pcDNA3.1(+) 基础上,通过脂质体转染方法将 NGX6 基因导入鼻咽癌细胞株 SUNE-1 的亚株 5-8F 细胞 ( 具高成瘤高转移潜能 ) 中,并用 RT-PCR 和 RNA 印迹鉴定,建立了稳定表达 NGX6 基因的 5-8F 细胞系 . 借助细胞生长曲线、软琼脂集落形成实验对转染细胞的生物学行为进行了检测,同时采用包含 1 176 个与肿瘤学相关的基因 cDNA 微阵列,分析了 NGX6 基因转染对 5-8F 细胞基因表达谱的影响 . 结果显示：转染了 NGX6 基因的 5-8F 细胞的生长速度明显减慢,在软琼脂中集落形成率较对照组显著下降 (P < 0.05) ,发现 NGX6 基因的转染能够上调 5-8F 细胞中 p19 、 catenin α 2 、 desmoglein 1 等基因的表达,同时下调 EphB4 、 TIE2 、 vitronectin 等基因的表达 . 综上所述, NGX6 基因可以抑制 5-8F 细胞的恶性生物学行为,并影响一些与细胞周期、细胞黏附和血管生成有关的基因的表达 . 上述结果为鼻咽癌转移分子机制的阐明提供了重要的线索 .     

利用cDNA微阵列-CGH筛选支气管上皮细胞恶性转化中的扩增基因

目的:基因组不稳定是导致肺癌发生与发展的重要分子机理之一。本研究旨在筛选支气管上皮细胞恶性转化过程中拷贝数扩增的基因。方法:利用业已建立的支气管上皮细胞体外恶性转化模型,通过cDNA微阵列-CGH技术对支气管上皮来源的永生化细胞和癌变细胞的基因拷贝数进行了检测,并对部分结果进行了实时PCR验证。结果:永生化BEP2D细胞染色体中的某些区域存在不同程度的扩增,包括5q31.3、9q32-33.1、14q22.2-23.1、19p13.12-13.13、20q13.12-13.31;恶性转化BERP35T2细胞染色体中的扩增区域集中在1p12-13.1、5q33.1、5q31.3、9q32、19p13.12-13.13;5q31.3、9q32、19q13.12-13.13是以上2种细胞系中的共同扩增区域。共检测到201个基因的拷贝数发生扩增,其中PCNA、TP53及GADD45A基因的异常扩增已经实时PCR进一步验证。结论:在支气管上皮细胞恶性转化过程中,病毒与低剂量辐射的双重作用使得某些重要基因的拷贝数发生扩增,因基因剂量增加而导致某些癌基因高表达可能是细胞恶性转化的重要机制之一。     

内皮抑素基因抗黑色素瘤细胞高转移的动物研究

目的:验证转内皮抑素基因抑制高转移性黑色素瘤细胞的转移能力.方法:将 pcDNA3.1-Endo 真核表达载体转染小鼠黑色素瘤高转移细胞株B16F10,运用RT-PCR和Western-blot验证Endo的表达后,进行瘤细胞的粘附实验、体外侵袭和运动实验以及C57BL/6小鼠的皮下种植瘤和肺转移瘤试验,并进一步统计分析.结果:内皮抑素基因能明显抑制B16F10黑色素瘤细胞的粘附、体外侵袭和运动、体内成瘤以及肺转移能力,其中粘附抑制率36.4%,体外侵袭抑制率48.4%,细胞运动功能抑制率52.1%,肺转移抑制率为67.3%.结论:转内皮抑素基因能明显抑制黑色素瘤细胞的高转移能力.     

2型糖尿病易感基因的连锁和关联研究

2型糖尿病（T2DM）是由于胰岛素抵抗和β细胞分泌缺陷导致高血糖的一种复杂多基因疾病。遗传因素在T2DM的发生发展中起着重要的作用,其遗传率估计为70％～80％。鉴定2型糖尿病基因将有助于阐明其发病机制,发展更好的诊断、预防和治疗策略。2型糖尿病易感基因的鉴定方法主要有候选基因关联研究和全基因组连锁分析。有3种类型的候选基因：功能候选基因、图位候选基因和表达候选基因。虽然许多候选基因与T2DM的关联分析已经进行,但多数都没有得到一致的重复,过氧化物酶体增殖物激活受-γ,体和β-细胞ATP敏感性钾通道基因是目前最好重复的基因。迄今为止,T2DM的全基因组扫描已在20多个不同的群体中进行,包括欧洲人、美国白人、墨西哥裔美国人、美国本地印度人、非洲裔美国人和亚洲人,这些研究鉴定了一些与T2DM相关的QTLs区域。与T2DM显著和证实连锁的区域包括1q25、2q37．3q28、3p24、6q22、8p23、10q26、12q24、18p11、20q13等,与T2DM提示连锁的区域有1q42、2p21、2q24、4q34、5q13、5q31、7q32、9p24、9q21、10p14、11p13、11q13、12q15、14q23、20p12、Xq23等。鉴定这些区域的T2DMQTLs基因及其作用机制是未来的主要挑战。把DNA微阵列和蛋白质组学技术结合起来应用于传统的连锁分析和关联研究,研究基因-基因间、基因-环境间的互作和多个基因对T2DM的加性效应和综合作用,进一步加强国际协作,T2DM的遗传机制可望在不远的将来得到阐明。本文总结了2型糖尿病基因鉴定的现状,重点在一些得到重复的区域和未来的展望。     

利用CRISPR/Cas系统构建在XRCC6内源基因插入Flag标签序列的HeLa细胞系

目的:利用CRISPR/Cas系统在XRCC6基因5′端插入Flag标签序列,筛选XRCC6-Flag稳定表达的宫颈癌细胞(He La)株。方法:根据Gen Bank中XRCC6基因序列,设计XRCC6基因敲入的g RNA序列,构建入p Cas-Guide载体中,获得p Cas-XRCC6载体;设计XRCC6基因的同源臂序列,利用搭桥PCR方法将同源臂和Flag标签序列作为模板进行扩增,得到供体DNA片段,并将其克隆到p Back Zero-T表达载体上,获得p XRCC6-Donor载体;将上述2个载体共转染He La细胞,采用PCR、Western印迹等方法检测和筛选Flag标签序列插入XRCC6基因5′端的细胞株。结果:构建了p Cas-XRCC6和p XRCC6-Donor载体,筛选获得3株XRCC6-Flag稳定表达细胞株。结论:构建了XRCC6-Flag稳定细胞株,为研究XRCC6基因及其蛋白产物的生物学功能奠定了基础。     

细胞凋亡和代谢基因在转移倾向结肠癌中的研究

目的:应用基因微阵列技术初步筛选与不同转移倾向结肠癌相关的细胞凋亡和代谢相关基因,研究转移相关基因功能.方法:取结肠癌肝转移和无转移结肠癌组织,采用人全基因组表达谱芯片获得两组织的基因表达谱,分析比较两者之间细胞凋亡和代谢基因的差异表达情况;利用基因数据库检索结肠癌相关基因,分析基因功能.结果:应用含有16450个克隆(其中3869个未知)的cDNA微阵列分析发现,细胞凋亡或肿瘤相关基因中,2倍以上(Ratio值小于0.5或大于2.0)差异基因共216个,上调基因85个,下调基因129个.表达差异5倍以上(Ratio值小于0.2或大于5.0)共32个,上调基因10个,下调基因22个.在细胞代谢相关基因中,2倍以上(Ratio值小于0.5或大于2.O)差异基因共205个,上调基因86个,下调基因119个.表达差异5倍以上(Ratio值小于0.2或大于5.0)共15个,上调基因10个,下调基因5个.利用基因数据库检索分析发现5个基因与结肠癌转移关系密切.结论:结肠癌的发生和转移是多基因参与的,本实验应用基因微阵列技术发现细胞凋亡和代谢相关基因中发现5个基因与结肠癌转移关系密切.     

一个在肝癌中表达下调的基因syap1的克隆和鉴定

肿瘤细胞区别于正常细胞的最基本特征是细胞生长失控和分化受阻。这种细胞生长失控和分化受阻是由于多种遗传性缺陷积累的结果,这主要表现在两个方面:一是癌基因的激活或过度表达,阻止细胞分化,促进细胞生长;另一方面是肿瘤抑制基因的失活。在肝癌研究中人们发现有多处染色体DNA发生缺失如染色体1p、4q、5q、6q、8p、10p、11p、13q、16q、17p和22q区域,提示这些区域可能存在肿瘤抑制基因。其中13q、17p和8p区域的肿瘤抑制     

NGX6基因转染对鼻咽癌细胞基因表达谱的影响

鼻咽癌是我国南方的常见肿瘤 .NGX6是新近克隆的定位于 9p2 1 2 2 ,在鼻咽癌组织中表达下调的基因 .初步的研究结果显示 ,NGX6基因转染鼻咽癌细胞HNE1能够延缓其生长速度 ,使肿瘤细胞更多地停留在G0 G1期 .为探索NGX6基因在鼻咽癌发病机制中的作用 ,建立了高表达NGX6的鼻咽癌细胞系 .利用包含 14 0 0 0个基因的cDNA微阵列分析了NGX6基因转染对HNE1细胞基因表达谱的影响 ,发现NGX6基因的转染能够上调p2 9、APC7、NEU1、RNasek6、αE catenin和TFⅡEα等基因的表达 ;同时也下调properdinP因子、G0S2、BAZ2B、ZHX1,OS4和PBX3等基因的表达 .研究结果提示 ,NGX6基因对鼻咽癌细胞的生物学行为的影响可能与它对一些细胞周期调控因子和转录调控因子的影响相关 .作为一种高通量的分析技术 ,cDNA微阵列为新基因的功能研究提供了重要的线索     

RKIP低表达与鼻咽癌侵袭转移和NF-κB信号通路活化相关

为筛选鼻咽癌(nasopharyngeal carcinoma,NPC)发病相关的蛋白质,采用双向凝胶电泳(two-dimensional electrophoresis,2-DE)和质谱(mass spectrometry,MS)技术比较NPC组织与癌旁正常鼻咽上皮组织(adjacent normal nasopharyngeal epithelial tissue,ANNET)蛋白质表达的差异,鉴定了21个差异蛋白,其中Raf 激酶抑制蛋白(Raf kinase inhibitor protein,RKIP)等9个蛋白质在NPC组织中的表达水平低于ANNET．为探讨RKIP在NPC转移中的作用和机制,采用Western blot检测RKIP在不同转移潜能的5-8F和6-10B NPC细胞中的表达水平,采用免疫组化方法检查RKIP在石蜡包埋NPC组织、正常鼻咽上皮组织(normal nasopharyngeal epithelial tissue,NNET))及颈淋巴结转移NPC组织(lymphnode metastatic NPC,LMNPC)中的表达水平,采用脂质体转染方法将正义、反义RKIP表达质粒及其相应空白载体分别转染5-8F和6-10B细胞,建立相应的稳定转染细胞系,分析RKIP表达水平改变对NPC细胞体外侵袭能力和NF-κB信号通路活性的影响．结果显示：RKIP在高转移5-8F细胞中的表达水平低于非转移6-10B细胞、在NPC组织中的表达水平低于NNET、在转移癌中表达缺失．上调RKIP表达能抑制5-8F细胞的侵袭能力,而下调RKIP表达能增强6-10B细胞的侵袭能力;上调RKIP表达能降低5-8F细胞的p-IκB-α水平和NF-κB的转录活性,而下调RKIP表达能增加6-10B细胞的p-IκB-α水平和NF-κB的转录活性．研究结果提示,RKIP 可能是NPC的一个转移抑制蛋白,RKIP表达下调可能通过活化NF-κB信号通路促进NPC细胞侵袭和转移．     

应用cDNA微阵列技术研究EB病毒LMP1介导的鼻咽癌中转移相关基因的表达

探讨EB病毒基因组编码的癌蛋白LMP1对鼻咽癌细胞中转移相关基因表达的影响.采用蛋白质印迹法检测在强力霉素(Dox)诱导下,鼻咽癌细胞系pTet-on-LMP1 HNE2(L7细胞)中LMP1表达的时效和量效关系.应用cDNA微阵列技术建立诱导性LMP1介导鼻咽癌细胞中转移相关基因差异表达谱;运用RT-PCR验证cDNA微阵列筛选差异基因表达的可靠性.与LMP1不表达的L7细胞比较,LMP1高表达的L7细胞中7个基因的表达显著上调,12个基因的表达显著下调.随机选择其中4个基因进行RT-PCR,结果显示,这些基因表达阳性,且与微阵列中的变化趋势一致.LMP1可能通过激活和/或抑制一些转移相关基因的表达而参与鼻咽癌转移过程.     

High frequency of common DNA copy number abnormalities detected by bacterial artificial chromosome array comparative genomic hybridization in 24 breast cancer cell lines

Breast cancer is a widespread disease in Japan and across the world. Breast cancer cells, as well as most other types of cancer cells, have diverse chromosomal aberrations. Clarifying the character of these chromosomal aberrations should contribute to the development of more suitable therapies, along with the predictions of metastasis and prognosis. Twenty-four breast cancer cell lines were analyzed by bacterial artificial chromosome (BAC) array comparative genomic hybridization (CGH). The array slide contained duplicate spots of 4030 BAC clone DNAs covering the entire human genome with 1 Mbp resolution. In all 24 breast cancer cell lines, frequent and significant amplifications as well as deletions were detected by BAC array CGH. Common DNA copy number gains, detected in 60% (above 15 cell lines) of the 24 breast cancer cell lines were found in 76 BAC clones, located at 1q, 5p, 8q, 9p, 16p, 17q, and 20q. Moreover, common DNA copy number loss was detected in 136 BAC clones, located at 1q, 2q, 3p, 4p, 6q, 8p, 9p, 11p, 13q, 17p, 18q, 19p, Xp, and Xq. The DNA copy number abnormalities found included abnormality of the well-known oncogene cMYC (8q24.21); however, most of them were not reported to relate to breast cancer. BAC array CGH has great potential to detect DNA copy number abnormalities, and has revealed that breast cancer cell lines have substantial heterogeneity.     

A genome-wide study of cytogenetic changes in colorectal cancer using SNP microarrays: opportunities for future personalized treatment

In colorectal cancer (CRC), chromosomal instability (CIN) is typically studied using comparative-genomic hybridization (CGH) arrays. We studied paired (tumor and surrounding healthy) fresh frozen tissue from 86 CRC patients using Illumina's Infinium-based SNP array. This method allowed us to study CIN in CRC, with simultaneous analysis of copy number (CN) and B-allele frequency (BAF)--a representation of allelic composition. These data helped us to detect mono-allelic and bi-allelic amplifications/deletion, copy neutral loss of heterozygosity, and levels of mosaicism for mixed cell populations, some of which can not be assessed with other methods that do not measure BAF. We identified associations between CN abnormalities and different CRC phenotypes (histological diagnosis, location, tumor grade, stage, MSI and presence of lymph node metastasis). We showed commonalities between regions of CN change observed in CRC and the regions reported in previous studies of other solid cancers (e.g. amplifications of 20q, 13q, 8q, 5p and deletions of 18q, 17p and 8p). From Therapeutic Target Database, we identified relevant drugs, targeted to the genes located in these regions with CN changes, approved or in trials for other cancers and common diseases. These drugs may be considered for future therapeutic trials in CRC, based on personalized cytogenetic diagnosis. We also found many regions, harboring genes, which are not currently targeted by any relevant drugs that may be considered for future drug discovery studies. Our study shows the application of high density SNP arrays for cytogenetic study in CRC and its potential utility for personalized treatment.     

From amplification to gene in thyroid cancer: a high-resolution mapped bacterial-artificial-chromosome resource for cancer chromosome aberrations guides gene discovery after comparative genome hybridization.

Chromosome rearrangements associated with neoplasms provide a rich resource for definition of the pathways of tumorigenesis. The power of comparative genome hybridization (CGH) to identify novel genes depends on the existence of suitable markers, which are lacking throughout most of the genome. We now report a general approach that translates CGH data into higher-resolution genomic-clone data that are then used to define the genes located in aneuploid regions. We used CGH to study 33 thyroid-tumor DNAs and two tumor-cell-line DNAs. The results revealed amplifications of chromosome band 2p21, with less-intense amplification on 2p13, 19q13.1, and 1p36 and with least-intense amplification on 1p34, 1q42, 5q31, 5q33-34, 9q32-34, and 14q32. To define the 2p21 region amplified, a dense array of 373 FISH-mapped chromosome 2 bacterial artificial chromosomes (BACs) was constructed, and 87 of these were hybridized to a tumor-cell line. Four BACs carried genomic DNA that was amplified in these cells. The maximum amplified region was narrowed to 3-6 Mb by multicolor FISH with the flanking BACs, and the minimum amplicon size was defined by a contig of 420 kb. Sequence analysis of the amplified BAC 1D9 revealed a fragment of the gene, encoding protein kinase C epsilon (PKCepsilon), that was then shown to be amplified and rearranged in tumor cells. In summary, CGH combined with a dense mapped resource of BACs and large-scale sequencing has led directly to the definition of PKCepsilon as a previously unmapped candidate gene involved in thyroid tumorigenesis.     

利用GenMAPP筛查鼻咽癌差异表达基因

利用GenMAPP软件对鼻咽癌和正常鼻咽上皮基因微阵列表达谱结果进行分析,筛查鼻咽癌差异表达基因. 结果显示：在17 000个基因中,与正常鼻咽上皮相比,在鼻咽癌中发生2倍以上差异表达的基因共有339个,其中有160个基因在鼻咽癌中表达上调,179个表达下调. 这些基因分别与细胞增殖、基因转录、凋亡、信号转导、DNA损伤修复、肿瘤分化和浸润转移及细胞周期调节等相关. 鼻咽癌的发生发展存在多基因表达调控的改变,对其差异表达基因的研究有助于阐明鼻咽癌发生发展机制.     

Gene amplification profiling of esophageal squamous cell carcinomas by DNA array CGH

Gene amplification is one of the basic mechanisms that lead to overexpression of oncogenes. DNA array comparative genomic hybridization (CGH) has great potential for comprehensive analysis of both a relative gene-copy number and altered chromosomal regions in cancers, which enables us to identify new amplified genes and unstable chromosomal loci. We examined the amplification status in 32 esophageal squamous cell carcinomas (ESCCs) and 13 ESCC cell lines on 51 frequently amplified loci in a variety of cancers by both DNA array CGH and Southern blot analyses. The 1p34 locus containing MYCL1, 2p24 (MYCN), 7p12 (EGFR), and 12q14 (MDM2) were amplified in one of the 32 cases (3%), and the 17q12 locus (ERBB2) and 8p11 (FGFR1) in two of the 32 cases (6%), while only the 11q13 locus (Cyclin D1, FGF4, and EMS1) was frequently amplified (28%, 9/32), demonstrating this locus to be a major target in ESCCs. One locus, 8q24 (c-MYC) was found to be amplified only in the cell lines. Eight out of 51 loci (15.7%) were found to be amplified in at least one of the 32 primary ESCCs or the 13 ESCC cell lines, suggesting that chromosomal loci frequently amplified in a type of human cancer may also be amplified in other types of cancers. This paper is the first report of an application of DNA array CGH to ESCCs.     

Ring chromosome 15: characterization by array CGH

Ring chromosome 15 [r(15)] is an uncommon finding with less than 50 patients reported. Precise genotype–phenotype correlations are problematic because of the difficulties in determining the extent of euchromatic loss, the level of mosaicism, and the influence of the timing of ascertainment. We report two discordant examples of r(15) patients. In the first case, prenatal diagnosis of a de novo r(15) was made during the second trimester: mos 46,XX,r(15)(p11.2q26)[32]/45,XX,-15[13]/47,XX,r(15)(p11.2q26)x2[3]/46,XX,dic r(15)(p11.2q26p11.2q26[1]/46,XX[2]. Postnatal follow-up revealed extremely small stature, heart defects, and developmental delay. Patient 2 was a 31-year-old short-statured female who was living independently: 46,XX,r(15)(p11q26). Both cases showed loss of the 15q subtelomeric region by fluorescence in situ hybridization (FISH). To investigate the discordance in phenotypes between the two patients, we undertook array comparative genomic hybridization (array CGH) analyses to more fully characterize the deletions associated with these otherwise structurally indistinguishable r(15) chromosomes from conventional cytogenetic analyses and fluorescence in situ hybridization (FISH) studies. By array CGH, patient 1 showed deletion of multiple contiguous clones predicting an approximately 6 Mb deletion of distal 15q. In contrast, patient 2 showed loss of just the 15q subtelomeric clone and an interstitial clone by array CGH confirming that the severity of the phenotype correlated with the size of the deletion at the molecular level. These cases illustrate the utility of array CGH characterization for determining the size of the associated deletion in ring chromosomes and for facilitating phenotype–genotype correlations.     

Genomic profiling of submucosal-invasive gastric cancer by array-based comparative genomic hybridization

Genomic copy number aberrations (CNAs) in gastric cancer have already been extensively characterized by array comparative genomic hybridization (array CGH) analysis. However, involvement of genomic CNAs in the process of submucosal invasion and lymph node metastasis in early gastric cancer is still poorly understood. In this study, to address this issue, we collected a total of 59 tumor samples from 27 patients with submucosal-invasive gastric cancers (SMGC), analyzed their genomic profiles by array CGH, and compared them between paired samples of mucosal (MU) and submucosal (SM) invasion (23 pairs), and SM invasion and lymph node (LN) metastasis (9 pairs). Initially, we hypothesized that acquisition of specific CNA(s) is important for these processes. However, we observed no significant difference in the number of genomic CNAs between paired MU and SM, and between paired SM and LN. Furthermore, we were unable to find any CNAs specifically associated with SM invasion or LN metastasis. Among the 23 cases analyzed, 15 had some similar pattern of genomic profiling between SM and MU. Interestingly, 13 of the 15 cases also showed some differences in genomic profiles. These results suggest that the majority of SMGCs are composed of heterogeneous subpopulations derived from the same clonal origin. Comparison of genomic CNAs between SMGCs with and without LN metastasis revealed that gain of 11q13, 11q14, 11q22, 14q32 and amplification of 17q21 were more frequent in metastatic SMGCs, suggesting that these CNAs are related to LN metastasis of early gastric cancer. In conclusion, our data suggest that generation of genetically distinct subclones, rather than acquisition of specific CNA at MU, is integral to the process of submucosal invasion, and that subclones that acquire gain of 11q13, 11q14, 11q22, 14q32 or amplification of 17q21 are likely to become metastatic.     

Integrated Genomic Analysis Implicates Haploinsufficiency of Multiple Chromosome 5q31.2 Genes in De Novo Myelodysplastic Syndromes Pathogenesis

Deletions spanning chromosome 5q31.2 are among the most common recurring cytogenetic abnormalities detectable in myelodysplastic syndromes (MDS). Prior genomic studies have suggested that haploinsufficiency of multiple 5q31.2 genes may contribute to MDS pathogenesis. However, this hypothesis has never been formally tested. Therefore, we designed this study to systematically and comprehensively evaluate all 28 chromosome 5q31.2 genes and directly test whether haploinsufficiency of a single 5q31.2 gene may result from a heterozygous nucleotide mutation or microdeletion. We selected paired tumor (bone marrow) and germline (skin) DNA samples from 46 de novo MDS patients (37 without a cytogenetic 5q31.2 deletion) and performed total exonic gene resequencing (479 amplicons) and array comparative genomic hybridization (CGH). We found no somatic nucleotide changes in the 46 MDS samples, and no cytogenetically silent 5q31.2 deletions in 20/20 samples analyzed by array CGH. Twelve novel single nucleotide polymorphisms were discovered. The mRNA levels of 7 genes in the commonly deleted interval were reduced by 50% in CD34+ cells from del(5q) MDS samples, and no gene showed complete loss of expression. Taken together, these data show that small deletions and/or point mutations in individual 5q31.2 genes are not common events in MDS, and implicate haploinsufficiency of multiple genes as the relevant genetic consequence of this common deletion.